{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:56:48Z","timestamp":1782295008047,"version":"3.54.5"},"reference-count":62,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Base pairing based on hydrogen bonding has, since its inception, been crucial in the antiviral activity of arabinosyladenine, 2\u2032-deoxyuridines (i.e., IDU, TFT, BVDU), acyclic nucleoside analogues (i.e., acyclovir) and nucleoside reverse transcriptase inhibitors (NRTIs). Base pairing based on hydrogen bonding also plays a key role in the mechanism of action of various acyclic nucleoside phosphonates (ANPs) such as adefovir, tenofovir, cidofovir and O-DAPYs, thus explaining their activity against a wide array of DNA viruses (human hepatitis B virus (HBV), human immunodeficiency (HIV) and human herpes viruses (i.e., human cytomegalovirus)). Hydrogen bonding (base pairing) also seems to be involved in the inhibitory activity of Cf1743 (and its prodrug FV-100) against varicella-zoster virus (VZV) and in the activity of sofosbuvir against hepatitis C virus and that of remdesivir against SARS-CoV-2 (COVID-19). Hydrogen bonding (base pairing) may also explain the broad-spectrum antiviral effects of ribavirin and favipiravir. This may lead to lethal mutagenesis (error catastrophe), as has been demonstrated with molnutegravir in its activity against SARS-CoV-2.<\/jats:p>","DOI":"10.3390\/v15051145","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T01:37:09Z","timestamp":1683769029000},"page":"1145","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hydrogen Bonding (Base Pairing) in Antiviral Activity"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[{"name":"Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/171737a0","article-title":"Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid","volume":"171","author":"Watson","year":"1953","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1021\/ja01495a070","article-title":"Potential anticancer agents. 1 xl. synthesis of the \u03b2-anomer of 9-(d-arabinofuranosyl)-adenine","volume":"82","author":"Lee","year":"1960","journal-title":"J. Am. Chem. Soc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0079-6603(08)60231-7","article-title":"Introduction to the biochemistry of D-arabinosyl nucleosides","volume":"5","author":"Cohen","year":"1966","journal-title":"Prog. Nucleic Acid Res. Mol. Biol."},{"key":"ref_4","first-page":"2725","article-title":"Effect of 2 arabinose nucleosides on the multiplication of herpes virus and vaccine in cell culture","volume":"259","year":"1964","journal-title":"Comptes Rendus Hebd. S\u00e9ances L\u2019acad\u00e9mie Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJM197605272942201","article-title":"Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study","volume":"294","author":"Whitley","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJM197708112970601","article-title":"Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. National Institute of Allergy and Infectious Diseases collaborative antiviral study","volume":"297","author":"Whitley","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJM199102143240703","article-title":"A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group","volume":"324","author":"Whitley","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-3002(59)90597-9","article-title":"Synthesis and biological activities of iododeoxyuridine, an analog of thymidine","volume":"32","author":"Prusoff","year":"1959","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_9","first-page":"92","article-title":"Studies on the mechanism of action of 5-iododeoxyuridine, an analog of thymidine","volume":"20","author":"Prusoff","year":"1960","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3181\/00379727-107-26560","article-title":"Plaque inhibition test for detection of specific inhibitors of DNA containing viruses","volume":"107","author":"Herrman","year":"1961","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3181\/00379727-109-27169","article-title":"Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine","volume":"109","author":"Kaufman","year":"1962","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1126\/science.145.3632.585","article-title":"Therapeutic antiviral action of 5-trifluoromethyl-2\u2032-deoxyuridine in herpes simplex keratitis","volume":"145","author":"Kaufman","year":"1964","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/infdis\/141.5.563","article-title":"Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus","volume":"141","author":"Descamps","year":"1980","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1073\/pnas.76.6.2947","article-title":"(E)-5-(2-Bromovinyl)-2\u2032-deoxyuridine: A potent and selective anti-herpes agent","volume":"76","author":"Descamps","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/bmj.281.6249.1178","article-title":"Oral (E)-5-(2-bromovinyl)-2\u2032-deoxyuridine in severe herpes zoster","volume":"281","author":"Degreef","year":"1980","journal-title":"Br. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/147.3.576","article-title":"Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus","volume":"147","author":"Shigeta","year":"1983","journal-title":"J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/0165-6147(82)91251-2","article-title":"Selective antiherpes agents","volume":"3","year":"1982","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/272583a0","article-title":"9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group","volume":"272","author":"Schaeffer","year":"1978","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","article-title":"Phosphorylation of 3\u2032-azido-3\u2032-deoxythymidine and selective interaction of the 5\u2032-triphosphate with human immunodeficiency virus reverse transcriptase","volume":"83","author":"Furman","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/jm00358a029","article-title":"Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]","volume":"26","author":"Colla","year":"1983","journal-title":"J. Med. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3\u2032-Azido-3\u2032-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1073\/pnas.83.6.1911","article-title":"Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III\/lymphadenopathy-associated virus (HTLV-III\/LAV) by 2\u2032,3\u2032-dideoxynucleosides","volume":"83","author":"Mitsuya","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","article-title":"Both 2\u2032,3\u2032-dideoxythymidine and its 2\u2032,3\u2032-unsaturated derivative (2\u2032,3\u2032-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro","volume":"142","author":"Baba","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/AAC.31.6.907","article-title":"Inhibitory effect of 2\u2032,3\u2032-didehydro-2\u2032,3\u2032-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus","volume":"31","author":"Hamamoto","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/0006-2952(87)90287-5","article-title":"Potent and selective in vitro activity of 3\u2032-deoxythymidin-2\u2032-ene (3\u2032-deoxy-2\u2032,3\u2032-didehydrothymidine) against human immunodeficiency virus","volume":"36","author":"Lin","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00002030-198907000-00001","article-title":"Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group","volume":"3","author":"Rooke","year":"1989","journal-title":"Aids"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1128\/AAC.38.7.1590","article-title":"5-Chloro-2\u2032,3\u2032-dideoxy-3\u2032-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile","volume":"38","author":"Daluge","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/AAC.36.11.2423","article-title":"Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"Rosenberg","year":"1986","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"Sakuma","year":"1987","journal-title":"Antivir. Res"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.46.7.2185-2193.2002","article-title":"Antiretrovirus activity of a novel class of acyclic pyrimidine nucleoside phosphonates","volume":"46","author":"Balzarini","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1021\/jm030932o","article-title":"5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity","volume":"46","author":"Andrei","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jac\/dkl454","article-title":"Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines","volume":"59","author":"Balzarini","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1128\/AAC.49.3.1177-1180.2005","article-title":"Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities","volume":"49","author":"Ying","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1074\/jbc.M109.096529","article-title":"The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization","volume":"285","author":"Herman","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"De Clercq, E. (2022). FV-100 for the treatment of varicella-virus (VZV) infections: Quo vadis?. Viruses, 14.","DOI":"10.3390\/v14040770"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1071\/MA21013","article-title":"Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19)","volume":"42","year":"2021","journal-title":"Microbiol. Aust."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.bmcl.2012.02.105","article-title":"Synthesis and antiviral activity of a series of 1\u2032-substituted 4-aza-7,9-dideazaadenosine C-nucleosides","volume":"22","author":"Cho","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","article-title":"Prodrugs of a 1\u2032-CN-4-aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the African Green monkey model of RSV","volume":"64","author":"Mackman","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/82191","article-title":"The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen","volume":"6","author":"Crotty","year":"2000","journal-title":"Nat. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1073\/pnas.111085598","article-title":"RNA virus error catastrophe: Direct molecular test by using ribavirin","volume":"98","author":"Crotty","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1126\/science.177.4050.705","article-title":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide","volume":"177","author":"Sidwell","year":"1972","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1073\/pnas.70.4.1174","article-title":"Mechanism of action of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent","volume":"70","author":"Streeter","year":"1973","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/JVI.79.3.1943-1947.2005","article-title":"The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase","volume":"79","author":"Leyssen","year":"2005","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/mol.105.020057","article-title":"The anti-yellow fever virus activity of ribavirin is independent of error-prone replication","volume":"69","author":"Leyssen","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/asia.201900841","article-title":"New nucleoside analogues for the treatment of hemorrhagic fever virus infections","volume":"14","year":"2019","journal-title":"Chem. Asian J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_52","first-page":"100080","article-title":"Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir","volume":"2","author":"Peng","year":"2021","journal-title":"Innovation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"106652","DOI":"10.1016\/j.bpc.2021.106652","article-title":"The mechanism of action of T-705 as a unique delayed chain terminator on influenza viral polymerase transcription","volume":"277","author":"Wang","year":"2021","journal-title":"Biophys. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hadj Hassine, I., Ben M\u2019hadheb, M., and Men\u00e9ndez-Arias, L. (2022). Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity. Viruses, 14.","DOI":"10.3390\/v14040841"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/em.22471","article-title":"Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir","volume":"63","author":"Waters","year":"2022","journal-title":"Environ. Mol. Mutagen"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41594-021-00657-8","article-title":"Molnupiravir: Coding for catastrophe","volume":"28","author":"Malone","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0027-5107(80)90218-3","article-title":"N4-hydroxycytidine: A mutagen specific for AT to GC transitions","volume":"72","author":"Janion","year":"1980","journal-title":"Mutat. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1126\/science.1259210","article-title":"Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase","volume":"347","author":"Appleby","year":"2015","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/0976-500X.142464","article-title":"Sofosbuvir: A novel treatment option for chronic hepatitis C infection","volume":"5","author":"Bhatia","year":"2014","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1060028014534194","article-title":"Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection","volume":"48","author":"Rose","year":"2014","journal-title":"Ann. Pharmacother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1574887108666131213120354","article-title":"Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era","volume":"9","author":"Gentile","year":"2014","journal-title":"Rev. Recent Clin. Trials"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/5\/1145\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:29Z","timestamp":1760124749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/5\/1145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":62,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["v15051145"],"URL":"https:\/\/doi.org\/10.3390\/v15051145","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]}}}